Prognostic value of expression of intracellular and extracellular domains of HER2 in patients with HER2-possitive breast cancer

Wspolczesna Onkologia

Volumn 15, Issue 5, 2011, Pages 267-273

  Dȩbska, Sylwia ^a   Kusińska, Renata ^a   Czernek, Urszula ^a   Szydłowska Pazera, Katarzyna ^a   Błasińska Morawiec, Maria ^b   Dowgier Witczak, Izabela ^b   Olas, Elzbieta ^b   Kulig, Andrzej ^c   Jakubiak Wielganowicz, Magdalena ^d   Potemski, Piotr ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Department of Teleradiotherapy   (Poland)

^c POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^d Ministry of Interior and Administration Republic of Poland Central Clinical Hospital   (Poland)

Author keywords

Extracellular domain; HER2; Intracellular domain; Trastuzumab

Indexed keywords

CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ETOPOSIDE; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG; VINORELBINE DITARTRATE;

ADULT; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASTECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREDICTIVE VALUE; PRIMARY TUMOR; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME;

EID: 82455181593     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2011.25654     Document Type: Article

References (38)

1. Berger MS, Locher GW, Saurer S, Guilick WJ, Waterfield MD, Groner B, Hynes NE. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988; 48: 1238-43. (Pubitemid 18075540)
2. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 103-12. (Pubitemid 20032452)
3. Gasparini G, Gullick WJ, Bevilacqua P, et al. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 1992; 10: 686-95.
4. McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BM, Carney DN. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 1991; 51: 3296-303.
5. Potemski P, Płuciennik E, Bednarek AK, et al. A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry. Med Sci Monit 2006; 12: MT57-61, 76.
6. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol 2009; 27: 5685-92.
7. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84. (Pubitemid 41464706)
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72. (Pubitemid 41464705)
9. Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 2008; 13: 620-30. (Pubitemid 351904907)
10. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares SV. Adjuvant trastuzumab in the treatment of Her-2-positive early breast cancer: ameta-analysis of published randomized trials. BMC Cancer 2007; 7: 153.
11. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus amonoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. N Engl J Med 2001; 344: 783-92. (Pubitemid 32222155)
12. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 Study Group. J Clin Oncol 2005; 23: 4265-74. (Pubitemid 46207001)
13. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-over-expressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26. (Pubitemid 34111379)
14. Baselga J, Carbonell X, Castaneda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23: 2162-71. (Pubitemid 46218708)
15. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010; 28: 1684-91.
16. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008; 26: 2373-8.
17. Ellis IO, Dowsett M, Bartlett J, Walker R. Recommendations for HER2 testing in the UK. J Clin Pathol 2000; 53: 890-2.
18. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14: 320-68.
19. Waterman H, Sabanai I, Geiger B, Yarden Y. Alternative intracellular routing of ErbB receptors may determine signaling potency. J Biol Chem 1998; 22: 13819-27.
20. Brennan JP, Kumogai T, Berezov A, Murali R, Greene M. HER2/Neu: mechanisms of dimerization/oligomerization. Oncogene 2000; 9: 6093-101. (Pubitemid 32059459)
21. Molina MA, Codony-Servat J, Albanell J, Rojo R, Arribas J, Baselga J. Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61: 4744-9. (Pubitemid 32691885)
22. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009; 27: 5685-92.
23. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84. (Pubitemid 41464706)
24. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72. (Pubitemid 41464705)
25. Rhodes A, Jasani B, Couturier J, et al. A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. Am J Clin Pathol 2002; 117: 81-9. (Pubitemid 34052476)
26. Ceccarelli C, Santini D, Gamberini M, et al. Immunohistochemical expression of internal and external ErbB-2 domains in invasive breast cancer. Breast Cancer Res Treat 1999; 58: 107-14. (Pubitemid 30032481)
27. Ainsworth R, Bartlett JM, Going JJ, et al. IHC for Her2 with CBE356 antibody is amore accurate predictor of Her2 gene amplification by FISH than HercepTestTM in breast carcinoma. J Clin Pathol 2005; 58: 1086-90. (Pubitemid 41416060)
28. Bussolati G, Montemurro F, Righi L, Donadio M, Aglietta M, Sapino A. Amodified trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. Br J Cancer 2005; 92: 1261-7. (Pubitemid 40604401)
29. Sapino A, Montemurro F, Marchio C, et al. Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. Ann Oncol 2007; 18: 1963-8. (Pubitemid 350286232)
30. Vinhas-Ricardo SA, Milanezi F, Carvalho ST, Aguilera-Leitao DR, Lander Schmitt FC. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol 2007; 60: 1001-5. (Pubitemid 47441932)
31. Arribas J, Parra-Palau JL, Pedersen K. HER2 fragmentation and breast cancer stratification. Clin Cancer Res 2010; 16: 4071-3.
32. Anido J, Scaltriti M, Serra JJ, et al. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 2006; 5: 3234-44. (Pubitemid 44106773)
33. Pedersen K, Angelini PD, Laos S, et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cel Bio 2009; 12: 3319-31.
34. Scaltriti M, Rojo F, Ocańa A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007; 99: 628-38.
35. Saez R, Molina MA, Ramsey EE, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006; 12: 424-31. (Pubitemid 43166131)
36. Molina MA, Saez R, Ramsey EE, et al. NH2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal meta-stasis in human breast cancer. Clin Cancer Res 2002; 8: 347-53. (Pubitemid 34193949)
37. Sperinde J, Jin X, Banerjee J, et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res 2010; 16: 4226-35.
38. Berger MS, Locher GW, Saurer S, Guilick WJ, Waterfield MD, Groner B, Hynes NE. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988; 48: 1238-43. (Pubitemid 18075540)